Cambridge Cognition Share Price, News & Analysis (LON:COG) GBX 54.50 0.00 (0.00%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range 53.94▼ 54.5050-Day Range 51▼ 94.8052-Week Range 50.55▼ 129.74Volume5,032 shsAverage Volume52,133 shsMarket Capitalization£19.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines About Cambridge Cognition Stock (LON:COG)Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.Read More COG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COG Stock News HeadlinesNovember 29, 2023 | msn.comHow to stop being fooled by misinformation, according to expertsNovember 27, 2023 | msn.comStudy Confirms Medical Marijuana For Chronic Conditions Does Not Harm Cognitive AbilitiesDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 27, 2023 | msn.comOur brain can't 'rewire' itself, say neuroscientists contradicting popular viewNovember 24, 2023 | msn.comUniversity of Cambridge scientists identify potential drug target for major cause of stroke and vascular dementiaOctober 30, 2023 | finance.yahoo.comGlobal Cognitive Assessment and Training in Healthcare Market Set to Soar, Anticipating $26.4 Billion by 2030October 12, 2023 | marketwatch.comCambridge Cognition Wins Contract Valued at GBP1MlnOctober 10, 2023 | msn.comBrain imaging study reveals peculiarities in uncertainty processing in obsessive-compulsive disorderDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 10, 2023 | msn.comOur fitness expert discusses the secret ingredient to feeling your best every dayOctober 9, 2023 | msn.comSpatial cognition improves when one is under energetic stress, study findsOctober 4, 2023 | msn.comWhy audiobooks can’t beat the real thingSeptember 30, 2023 | msn.comChild Development: 10 Essential Factors For Nurturing Emotional Well-Being In Early-Age ChildrenSeptember 30, 2023 | msn.comFishing and its health benefits: The more men go fishing, the better their mental health, study findsSeptember 29, 2023 | msn.comSam Altman Says He Intends to Replace Normal People With AISeptember 27, 2023 | msn.comTech bros keep obsessing about replacing the 'median human' with AISeptember 26, 2023 | lse.co.ukCambridge Cognition swings to interim loss amid ballooning costsSeptember 26, 2023 | marketwatch.comCambridge Cognition Shares Fall on Swing to Pretax Loss; Secures GBP3 Mln LoanSeptember 25, 2023 | msn.comWhy Gouda is good for you – healthy cheeses and the ones to avoidSeptember 25, 2023 | mirror.co.ukEarly childhood reading brings 'lifelong rewards' and is tied to better mental healthSeptember 25, 2023 | msn.comExperts: Shawn Fain's biting style is creating a moment, just like another UAW labor iconSeptember 25, 2023 | markets.businessinsider.comLEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in JapanSeptember 22, 2023 | msn.comPsychotherapists Flip Freudian Thinking on Treating DepressionSeptember 22, 2023 | msn.comSuppressing negative thoughts may actually be a good thingSeptember 21, 2023 | msn.comHaving negative thoughts? Here’s how to suppress them to improve mental healthSeptember 20, 2023 | msn.comSuppressing negative emotions may actually benefit your mental heath, study findsSeptember 20, 2023 | msn.comSuppressing negative thoughts may be good for mental health, study suggestsSee More Headlines Receive COG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cambridge Cognition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/22/2020Today12/02/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Health Information Services Sub-IndustryN/A SectorMedical Current SymbolLON:COG CUSIPN/A CIKN/A Webwww.cambridgecognition.com Phone44 1223 810 700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.11) Trailing P/E RatioN/A Forward P/E Ratio39.80 P/E GrowthN/ANet Income£-3,740,000.00 Net Margins-29.25% Pretax MarginN/A Return on Equity-630.55% Return on Assets-13.31% Debt Debt-to-Equity Ratio18.95 Current Ratio0.45 Quick Ratio0.96 Sales & Book Value Annual Sales£12.77 million Price / Sales1.49 Cash FlowGBX 12.65 per share Price / Cash Flow4.31 Book ValueGBX 3 per share Price / Book18.17Miscellaneous Outstanding Shares34,930,000Free FloatN/AMarket Cap£19.04 million OptionableNot Optionable Beta1.01 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Matthew William Stork (Age 55)CEO & Director Comp: $342kMr. Stephen Daniel Symonds (Age 48)CFO & Executive Director Comp: $203.31kMr. John HammondCo-FounderMr. Nick TaptiklisHead of Technology StrategyMs. Francesca Cormack Ph.D.Chief ScientistMr. Simon MerrittMarketing and Communications DirectorDr. Lisa Elizabeth Nolan Ph.D. (Age 61)Vice President Business Development Ms. Nicky AckerleyGlobal HR DirectorProf. Trevor RobbinsSenior ConsultantProf. Barbara Sahakian FMedSciFBPsS, Senior ConsultantMore ExecutivesKey CompetitorsRenalytixLON:RENXInduction Healthcare GroupLON:INHCFeedbackLON:FDBKIQ-AILON:IQAITrellus HealthLON:TRLSView All CompetitorsInsidersDebra LeevesBought 10,000 shares on 2/3/2023Total: £1.12 M ($112.00/share) COG Stock Analysis - Frequently Asked Questions How have COG shares performed in 2023? Cambridge Cognition's stock was trading at GBX 114 at the beginning of the year. Since then, COG stock has decreased by 52.2% and is now trading at GBX 54.50. View the best growth stocks for 2023 here. How were Cambridge Cognition's earnings last quarter? Cambridge Cognition Holdings Plc (LON:COG) announced its quarterly earnings data on Tuesday, September, 22nd. The company reported ($1.50) earnings per share (EPS) for the quarter. Cambridge Cognition had a negative net margin of 29.25% and a negative trailing twelve-month return on equity of 630.55%. What other stocks do shareholders of Cambridge Cognition own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambridge Cognition investors own include Interserve (IRV), Alio Gold Inc. (ALO.TO) (ALO), Concepta PLC (CPT.L) (CPT), European Metals (EMH), IntelGenx Technologies (IGXT), Oxford Biomedica (OXB), Syneos Health (SYNH), Travelers Companies (TRV), Amryt Pharma (AMYT) and AltynGold (ALTN). How do I buy shares of Cambridge Cognition? Shares of COG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:COG) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambridge Cognition Holdings Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.